Ivermectin has shown anti-inflammatory effects in laboratory and animal studies, but it has not been tested as an arthritis treatment in humans. No rheumatology organization recommends it for any form of arthritis, and it is not approved for this use. The evidence so far is limited to cell experiments and a single rat study, which puts it in the earliest possible stage of investigation.
What the Animal Research Shows
One study published in Fundamental and Clinical Pharmacology induced rheumatoid arthritis in rats using an immune-stimulating compound, then treated some of the animals with ivermectin. The rats receiving ivermectin showed significantly reduced joint inflammation, less bone erosion, and lower levels of inflammatory cells compared to untreated rats. On a visual scoring system that graded swelling and joint damage, the ivermectin group improved noticeably. The researchers noted that the effects were comparable to dexamethasone, a powerful corticosteroid commonly used for inflammatory conditions.
That sounds promising on the surface, but rat models of arthritis are artificially induced and don’t fully mirror the complexity of human autoimmune disease. Many drugs that reduce inflammation in rodents fail to work, or cause unacceptable side effects, when tested in people. This single animal study has not been followed by human trials for arthritis.
How Ivermectin Affects Inflammation
Ivermectin is primarily an antiparasitic drug, but researchers have been exploring its anti-inflammatory properties for other potential uses. A 2025 study in the International Journal of Molecular Sciences identified a specific mechanism: ivermectin binds to a site on proteins called integrins, blocking inflammatory signaling molecules like TNF, a key driver of rheumatoid arthritis. In cell-free experiments, ivermectin suppressed integrin activation by TNF and several other pro-inflammatory compounds in a dose-dependent manner, meaning higher concentrations produced stronger effects.
This matters because TNF is one of the central targets of existing rheumatoid arthritis drugs. Several widely prescribed biologic medications work specifically by neutralizing TNF. The fact that ivermectin can interfere with TNF signaling through a different pathway is scientifically interesting, but interfering with a pathway in a test tube is very different from safely and effectively treating a disease in a living person.
The Dosage Problem
One major hurdle is dosage. In humans, ivermectin is typically prescribed at 150 to 200 micrograms per kilogram of body weight for parasitic infections, taken as a single dose or a short course. The anti-inflammatory and anti-cancer effects seen in animal studies generally require doses around 5 mg/kg in mice, which translates to roughly 0.40 mg/kg in humans. That’s about two to three times higher than the standard antiparasitic dose.
Arthritis is a chronic condition requiring ongoing treatment, not a one-time dose. Whether ivermectin could safely be taken at elevated doses over weeks, months, or years is completely unknown. The safety data that exists for ivermectin is based on short-term use at lower doses for parasitic infections.
Safety Concerns With Prolonged Use
Ivermectin’s side effect profile at standard antiparasitic doses is relatively mild. Clinical trials for parasitic infections documented dizziness (2.8%), drowsiness (0.9%), vertigo (0.9%), and tremor (0.9%) as the most common drug-related neurological effects.
However, serious neurological events have been reported in broader use. A review in The American Journal of Tropical Medicine and Hygiene documented cases including encephalopathy, coma, and seizures. In one case, ivermectin was found in brain tissue. Several cases showed symptoms that returned when patients were re-exposed to the drug, strengthening the link between ivermectin and the neurological problems. Symptoms of neurotoxicity can include lethargy, tremors, seizures, disorientation, and inability to stand.
These serious events are rare at standard doses, but the risk picture changes substantially when you consider higher doses taken repeatedly over long periods, which is what arthritis treatment would require. No safety data exists for that scenario.
Where This Stands Compared to Proven Treatments
Rheumatoid arthritis has a well-established treatment toolkit. Disease-modifying drugs slow joint damage and can put the disease into remission. Biologic therapies that target specific immune molecules like TNF have transformed outcomes for many patients. These treatments have decades of human clinical trial data behind them, with known benefits, risks, and long-term safety profiles.
Ivermectin has none of that for arthritis. It has a plausible biological mechanism, one positive rat study, and no human data. In drug development terms, it hasn’t even reached the starting line of clinical testing for joint disease. Hundreds of compounds show promise in animal models of arthritis each year, and the vast majority never become viable treatments.
For someone managing arthritis symptoms, the current evidence does not support using ivermectin. The gap between “reduces inflammation in rats” and “safely treats arthritis in people” is wide, and no research has begun to bridge it.